Van Berkom & Associates Inc. Has $106.09 Million Holdings in Maximus, Inc. $MMS

Van Berkom & Associates Inc. lessened its stake in Maximus, Inc. (NYSE:MMS) by 8.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,161,125 shares of the health services provider’s stock after selling 104,474 shares during the quarter. Maximus comprises about 3.1% of Van Berkom & Associates Inc.’s investment portfolio, making the stock its 6th largest holding. Van Berkom & Associates Inc. owned about 2.06% of Maximus worth $106,092,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MMS. Royal Bank of Canada grew its holdings in Maximus by 146.2% during the first quarter. Royal Bank of Canada now owns 19,732 shares of the health services provider’s stock valued at $1,345,000 after purchasing an additional 11,716 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Maximus by 0.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,476 shares of the health services provider’s stock worth $2,351,000 after acquiring an additional 221 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Maximus by 7.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 180,690 shares of the health services provider’s stock valued at $12,321,000 after purchasing an additional 11,754 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Maximus by 941.2% during the 1st quarter. Jane Street Group LLC now owns 98,273 shares of the health services provider’s stock worth $6,701,000 after acquiring an additional 88,835 shares during the period. Finally, Sivia Capital Partners LLC bought a new stake in Maximus during the second quarter worth $204,000. Institutional investors own 97.21% of the company’s stock.

Maximus Trading Down 2.2%

Shares of MMS stock opened at $92.41 on Wednesday. The firm has a market cap of $5.04 billion, a P/E ratio of 16.62 and a beta of 0.57. The business has a 50-day moving average price of $90.31 and a two-hundred day moving average price of $86.36. The company has a quick ratio of 1.64, a current ratio of 1.64 and a debt-to-equity ratio of 0.77. Maximus, Inc. has a 12-month low of $63.77 and a 12-month high of $100.00.

Maximus (NYSE:MMS) last released its quarterly earnings data on Thursday, November 20th. The health services provider reported $1.62 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.01). The company had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.34 billion. Maximus had a net margin of 5.87% and a return on equity of 25.23%. The business’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the company posted $1.46 EPS. Maximus has set its FY 2026 guidance at 7.950-8.250 EPS. Equities analysts anticipate that Maximus, Inc. will post 6.15 EPS for the current fiscal year.

Maximus Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be issued a $0.33 dividend. This represents a $1.32 annualized dividend and a yield of 1.4%. This is an increase from Maximus’s previous quarterly dividend of $0.30. The ex-dividend date is Friday, February 13th. Maximus’s dividend payout ratio (DPR) is presently 21.58%.

Analyst Ratings Changes

A number of research analysts have recently commented on MMS shares. Zacks Research upgraded Maximus from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 30th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Maximus in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Strong Buy”.

Insider Transactions at Maximus

In other Maximus news, insider Michelle F. Link sold 4,039 shares of the company’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $86.84, for a total value of $350,746.76. Following the completion of the transaction, the insider directly owned 19,542 shares in the company, valued at approximately $1,697,027.28. This represents a 17.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.80% of the company’s stock.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.